2

Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods

*Pharmaceutical Statistics* 2021; doi:10.1002/pst.2119

MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy

*Cancer Medicine* 2021; doi:10.1002/cam4.3846

Analysing the Action Research Arm Test (ARAT): A cautionary tale from the RATULS trial

*International Journal of Rehabilitation Research* 2021; doi:10.1097/MRR.0000000000000466

Statistical consideration when adding new arms to ongoing clinical trials: The potentials and the caveats

*Trials* 2021; 22:203

Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers

*PLoS Genetics* 2021; 17(3):e1009254

A reply to 'Lung cancer outcomes: Are BMI and race clinically relevant?'

*Lung Cancer* 2021; doi:10.1016/j.lungcan.2021.02.019

Tumour gene expression signature in primary melanoma predicts long-term outcomes

*Nature Communications* 2021; 12:1137

The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients

*Lung Cancer* 2021; 152:58-65

Reproducibility of 19F‐MR ventilation imaging in healthy volunteers

*Magnetic Resonance in Medicine* 2021; 85(6):3343-3352

Use of proton pump inhibitors to treat persistent throat symptoms: Multicentre, double blind, randomised, placebo controlled trial

*BMJ* 2021; 372:m4903